首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3190篇
  免费   245篇
  国内免费   6篇
耳鼻咽喉   58篇
儿科学   227篇
妇产科学   103篇
基础医学   483篇
口腔科学   58篇
临床医学   244篇
内科学   659篇
皮肤病学   111篇
神经病学   135篇
特种医学   53篇
外科学   359篇
综合类   67篇
一般理论   1篇
预防医学   269篇
眼科学   137篇
药学   225篇
中国医学   16篇
肿瘤学   236篇
  2023年   13篇
  2022年   53篇
  2021年   104篇
  2020年   64篇
  2019年   72篇
  2018年   86篇
  2017年   72篇
  2016年   112篇
  2015年   109篇
  2014年   126篇
  2013年   138篇
  2012年   268篇
  2011年   255篇
  2010年   152篇
  2009年   134篇
  2008年   205篇
  2007年   180篇
  2006年   184篇
  2005年   172篇
  2004年   148篇
  2003年   130篇
  2002年   116篇
  2001年   50篇
  2000年   31篇
  1999年   39篇
  1998年   27篇
  1997年   12篇
  1996年   22篇
  1995年   15篇
  1994年   16篇
  1993年   14篇
  1992年   24篇
  1991年   20篇
  1990年   36篇
  1989年   27篇
  1988年   18篇
  1987年   18篇
  1986年   19篇
  1985年   18篇
  1984年   10篇
  1983年   11篇
  1982年   15篇
  1980年   7篇
  1979年   11篇
  1978年   12篇
  1976年   9篇
  1975年   6篇
  1973年   8篇
  1972年   5篇
  1961年   8篇
排序方式: 共有3441条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy.  相似文献   
5.
6.
7.
8.
Neurilemmoma is usually soimry, benign tumour derived from schwan cells of the Sheaths of peripheral cranial or autonomie nerves. In thehead and neck region it occurs most commonly in association with acoustic nerve within the skuil and is rely fottnd in the oral cavity (1,2). We report here two cases of the iongue diagnosed on histopathohgy.  相似文献   
9.
Intra-articular fractures of the proximal tibia present a wide spectrum of injury patterns with associated soft tissue injury. The last two decades have seen the techniques of management evolve from extensive open reduction and rigid internal fixation to arthroscopy-assisted minimal invasive surgery (MIS) and biologically benign internal fixation. The ultimate aim is to prevent the occurrence of late degenerative arthritis. This could be achieved in selected patients using minimal invasive surgery, which offers the advantages of better visualisation and management of intra-articular soft tissue injuries, confirmation of fracture reduction viewed from the joint surface, faster rehabilitation and fewer wound complications.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号